Connect with us

NEWS

Vermont Lawmakers Debate Psilocybin Legalization in Psychedelic Study Bill

Published

on

A bill that would create a study group to examine the potential benefits and risks of legalizing psilocybin, the active ingredient in magic mushrooms, is facing opposition from some Vermont lawmakers who want to remove the legalization provision from the legislation.

The Bill’s Background and Purpose

The bill, H. 309, was introduced by Rep. Brian Cina, a Progressive/Democrat, who said he wanted to start a conversation about the therapeutic potential of psilocybin and other psychedelic substances. The bill would establish a 13-member committee, composed of legislators, health professionals, and advocates, to review the scientific literature and make recommendations on how to regulate psilocybin in Vermont.

Cina said he was inspired by the recent legalization of psilocybin in Oregon, where voters approved a ballot measure in 2020 that allows licensed providers to offer psilocybin therapy to adults. He also cited the growing body of research that suggests psilocybin can help treat conditions such as depression, anxiety, addiction, and post-traumatic stress disorder.

“I think it’s important for us to be open-minded and look at the evidence and see what’s out there,” Cina said. “There are people who are suffering and who could benefit from these substances.”

The Opposition and Amendments

However, not everyone in the legislature is on board with Cina’s vision. Some lawmakers have expressed concerns about the safety and legality of psilocybin, as well as the political feasibility of passing such a bill.

Vermont Lawmakers Debate Psilocybin

Rep. Anne Donahue, a Republican, said she supports the idea of studying psychedelics, but not legalizing them. She proposed an amendment that would strike the legalization language from the bill and focus only on the study group.

“I think it’s premature to talk about legalization when we don’t have the information,” Donahue said. “I think it’s a distraction from the real purpose of the bill, which is to look at the science and the evidence.”

Donahue’s amendment was supported by Rep. Chip Troiano, a Democrat, who also introduced a separate bill, H. 423, that would decriminalize the possession of psilocybin and other drugs. Troiano said he thinks decriminalization is a more realistic and humane approach than legalization.

“I think legalization is a big leap,” Troiano said. “I think decriminalization is a step in the right direction, to reduce the stigma and the criminalization of people who use these substances.”

The Future of the Bill

The bill is currently in the House Committee on Government Operations, where it has not yet been voted on. Cina said he is open to compromise and amendments, but he hopes the bill will not lose its original intent.

“I’m not attached to the specific language of the bill, but I’m attached to the idea of exploring this issue and having a dialogue,” Cina said. “I think it’s a timely and relevant topic, and I think Vermont can be a leader in this area.”

The bill has also attracted the attention of some advocacy groups, such as the Vermont Psychedelic Society, which was founded by a group of health professionals who support the decriminalization and legalization of psychedelics. Rick Barnett, a clinical psychologist and addiction specialist, said he hopes the bill will advance and spark more public awareness and education.

“We’re very excited about this bill and the opportunity to have a conversation about psychedelics in Vermont,” Barnett said. “We think there’s a lot of potential for healing and transformation, and we want to share that with the people of Vermont.”

Harry is the editor of CBD STRAINS ONLY, his own independent publication about CBD, hemp and cannabis strains, the products made from them and the rules that govern their sale. He has been a journalist for ten years, first reporting and then editing, and the bulk of that time has gone to this beat. Product coverage rests on the certificate of analysis: he reads the third party lab reports for cannabinoid content, terpene profile, residual solvents, pesticides and heavy metals, compares the numbers with what the label claims, and names the gap when there is one. Strain write-ups draw on breeder records, seed bank listings and published genetics work rather than on forum lore. Legal thresholds for THC in hemp, licensing rules and labelling requirements are quoted from the statute or regulation itself, and every figure is checked before publication. The site keeps a public corrections policy. None of this is medical advice; cannabis law differs by jurisdiction, and readers with a health condition should consult a clinician before using any product. Mail to Harry goes to support@cbdstrainsonly.com.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending